<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202549</url>
  </required_header>
  <id_info>
    <org_study_id>k(2019)31</org_study_id>
    <nct_id>NCT04202549</nct_id>
  </id_info>
  <brief_title>Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT)</brief_title>
  <official_title>Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Intra-arterial Cocktail Therapy (INSIST-CT): a Prospective, Single Arm, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Sheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombolysis and endovascular thrombectomy are the most efficient treatments for acute&#xD;
      ischemic stroke patients in time window. Although sufficient recanalization after&#xD;
      thrombectomy is more than 80%, HERMES study indicated that nearly half of the ischemic stroke&#xD;
      patients under thrombectomy suffered obvious disability. Artery reocclusion, hemorrhagic&#xD;
      transformation, and no-reflow phenomenon are among the most important reasons of poor&#xD;
      prognosis of acute ischemic stroke patients. The investigators speculate that a combination&#xD;
      of argatroban, edaravone, and glucocorticoid may be helpful in preventing artery reocclusion,&#xD;
      hemorrhagic transformation, and no-reflow phenomenon. This study intends to explore the&#xD;
      safety, feasibility and efficacy of thrombectomy with sufficient recanalization bridged by&#xD;
      intra-arterial cocktail therapy in acute ischemic stroke patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of favorable outcome</measure>
    <time_frame>90 days</time_frame>
    <description>favorable outcome is defined as mRS 0-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of excellent outcome</measure>
    <time_frame>90 days</time_frame>
    <description>excellent outcome is defined as mRS 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of early neurological improvement</measure>
    <time_frame>48 hours</time_frame>
    <description>early neurological improvement is defined as more than 4 decrease in NIHSS</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of symptomatic intracranial haemorrhage</measure>
    <time_frame>48 hours</time_frame>
    <description>intracranial haemorrhage is defined as more than 4 increase in NIHSS caused by intracranial bleeding</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>intra-arterial cocktail therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intra-arterial cocktail therapy</intervention_name>
    <description>Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.</description>
    <arm_group_label>intra-arterial cocktail therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the&#xD;
             anterior circulation and met the criteria of mechanical thrombectomy.&#xD;
&#xD;
          3. Sufficient recanalization （TICI 2b-3）within 7 hours of stroke onset.&#xD;
&#xD;
          4. The availability of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. insufficient recanalization（TICI &lt; 2a）after endovascular treatment;&#xD;
&#xD;
          2. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage.&#xD;
&#xD;
        4. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ &lt;100000/mm3）.&#xD;
&#xD;
        5. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper&#xD;
        limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of&#xD;
        normal value) or requiring dialysis.&#xD;
&#xD;
        6. Severe uncontrolled hypertension (systolic blood pressure over 200mmHg or diastolic&#xD;
        blood pressure over 110 mmHg).&#xD;
&#xD;
        7. Patients with contraindication or allergic to any ingredient of drugs in our study.&#xD;
&#xD;
        8. Unsuitable for this clinical studies assessed by researcher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zi-Ai Zhao, Doctor</last_name>
    <phone>+86 17790998175</phone>
    <email>zhaoziai@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Tao, Master</last_name>
    <phone>+86 18802401698</phone>
    <email>1939908868@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>ShenYang</city>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zi-Ai Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

